Tuberculosis and Drug Delivery System: Clinical Trials in TB
Authors:
- 15 March 2023
- book chapter
- Published by Springer Nature
- p. 289-305
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- In Vitro Combination Studies of Benzothiazinone Lead Compound BTZ043 against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Discovery and Development of SQ109: A New Antitubercular Drug with a Novel Mechanism of ActionFuture Microbiology, 2012
- Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolonesEuropean Respiratory Journal, 2012
- Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals Are Uniformly Susceptible to BenzothiazinonesAntimicrobial Agents and Chemotherapy, 2010
- Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture ConversionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosisScience, 2009
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLOS Medicine, 2006